Pulmonary Manifestations and Fibrosis

The lungs are a frequent and prognostically important target in connective-tissue and inflammatory rheumatic diseases. Manifestations range from interstitial lung disease and progressive fibrosis to pleural disease, airway involvement, and pulmonary vascular disease. This topic surveys the spectrum of pulmonary involvement, with emphasis on interstitial lung disease and fibrosis.

Definition

Pulmonary manifestations of rheumatic disease are the parenchymal, airway, pleural, and vascular lung involvements that arise in connective-tissue and inflammatory rheumatic conditions, of which interstitial lung disease with fibrosis is a leading prognostic determinant.

Scope

The entry covers connective-tissue disease-associated interstitial lung disease (notably in systemic sclerosis, inflammatory myopathies, and rheumatoid arthritis), the patterns of lung injury and fibrosis, and other thoracic manifestations such as pleuritis and pulmonary hypertension. It is a reference overview and does not provide diagnostic algorithms or treatment guidance.

Core questions

• Which rheumatic diseases most commonly involve the lungs, and in what patterns?
• How does autoimmune inflammation lead to interstitial lung injury and fibrosis?
• What distinguishes connective tissue disease-associated interstitial lung disease from idiopathic pulmonary fibrosis?

Key concepts

• Connective tissue disease-associated interstitial lung disease
• Usual interstitial pneumonia and non-specific interstitial pneumonia patterns
• Progressive pulmonary fibrosis
• Pleuritis and pleural effusion
• Pulmonary arterial hypertension
• Myositis-associated and antisynthetase-associated lung disease

Mechanisms

Autoimmune inflammation and, in fibrosing disease, dysregulated repair drive injury to the alveolar epithelium and interstitium, with fibroblast activation and extracellular-matrix deposition producing fibrosis. Mechanistic understanding of fibrosis draws on idiopathic pulmonary fibrosis, where epithelial injury and aberrant wound healing are central; in rheumatic disease, disease-specific autoimmunity (for example in systemic sclerosis and inflammatory myopathies) initiates and sustains the process. Pulmonary vascular remodelling can additionally produce pulmonary hypertension, particularly in scleroderma-spectrum disease.

Clinical relevance

Interstitial lung disease is among the leading causes of mortality in systemic sclerosis and contributes substantially to outcomes in inflammatory myopathies and rheumatoid arthritis, which is why pulmonary status is integral to how these diseases are characterised. This entry describes those associations for reference and does not offer screening schedules or treatment recommendations.

Epidemiology

Interstitial lung disease is common in systemic sclerosis and is a major contributor to its mortality; it also occurs frequently in inflammatory myopathies (especially antisynthetase syndrome) and in a subset of rheumatoid arthritis. Reported frequencies depend on the disease, ascertainment method, and cohort, but lung involvement is consistently a key prognostic factor.

History

As connective-tissue diseases were characterised in detail, the lung emerged as a recurrent and outcome-defining target. Reviews of scleroderma and of inflammatory myopathies established interstitial lung disease as a central feature, while advances in idiopathic pulmonary fibrosis sharpened the conceptual model of fibrosing lung injury applied across rheumatic disease.

Debates

How should progressive fibrosing phenotypes across diseases be conceptualised?

Whether interstitial lung diseases of differing autoimmune origin share a common progressive-fibrosing trajectory analogous to idiopathic pulmonary fibrosis is a topic of ongoing discussion that shapes how the field classifies and studies these conditions.

Seminal works

• denton-khanna-2017
• dalakas-hohlfeld-2003
• lederer-martinez-2018

Frequently asked questions

Which rheumatic disease is most associated with lung fibrosis?

Systemic sclerosis is strongly associated with interstitial lung disease and fibrosis, which is a leading cause of its mortality; interstitial lung disease is also common in inflammatory myopathies and occurs in a subset of rheumatoid arthritis.

Is connective tissue disease-associated lung fibrosis the same as idiopathic pulmonary fibrosis?

No. They can share fibrotic patterns and mechanisms of injury, but connective tissue disease-associated interstitial lung disease arises in the context of a systemic autoimmune disease, whereas idiopathic pulmonary fibrosis occurs without an identified autoimmune cause.